Ex vivo purging of contaminating tumor cells may reduce the incidence of relapse in patients undergoing bone marrow transplantation. In this study we demonstrate that resveratrol, a phytoalexin with anti-oxidant and chemopreventive activity, exhibits anti-leukemic activity against mouse (32Dp210, L1210) and human (U937, HL-60) leukemic cell lines by inhibiting cell proliferation. Long-term exposure to resveratrol also inhibits the clonal growth of normal hematopoietic progenitor cells but at a higher IC 50 
cological agents that have been used for ex vivo purging of tumor cells include 4-hydroxyperoxycyclophosphamide, mafosfamide and VP-16. [8] [9] [10] [11] [12] These agents impair prompt engraftment of normal hematopoietic progenitor cells.
Resveratrol, a non-flavonoid polyphenolic compound naturally occurs in grapes and red wine prepared from them. Resveratrol has been shown to modulate lipoprotein metabolism, 13, 14 eicosanoid synthesis, [15] [16] [17] oxidation, 18 and platelet aggregation. 15, 19 Recently, resveratrol has also been demonstrated to inhibit cellular processes associated with tumor initiation, promotion, and progression. 20 In another study, resveratrol inhibited the proliferation of both estrogen receptor-positive and -negative breast cancer lines in vitro in a dose-and time-dependent manner. 21 The effect of resveratrol on the proliferation of normal and leukemic hematopoietic progenitors, has not been established. In this paper we demonstrate that, although resveratrol inhibits the growth of both normal hematopoietic progenitors and leukemic cells in a dose-related manner, the anti-proliferative effect on normal progenitors is less dramatic and is reversible.
Materials and methods

Agents
Trans-resveratrol (trans-3,4′,5-trihydroxy stilbene) was purchased from Sigma Chemical (St Louis, MO, USA). A 200 mm solution of resveratrol was prepared in DMSO and all test concentrations were prepared by diluting the appropriate amounts of stock solution in tissue culture medium. MethoCult 3534 culture medium was from Stem Cell Technologies (Vancouver, Canada).
Mice
Eight-to 10-week-old male C3H mice were purchased from Taconic Laboratories (Germantown, NY, USA). Mice were maintained in the Bioresource Facility of the Henry Ford Health System at One Ford Place. All animals were given mouse chow and acidified water ad libitum. Mice were housed for at least 1 week before experimental use and agematched animals were used within any given experiment.
Leukemia cell lines
Human leukemia cell lines HL-60 (promyelocytic) and U937 (monocytic), and mouse leukemia cell line L1210 (lymphocytic) were obtained from American Tissue Type Culture and maintained in RPMI-1640 supplemented with 10% FBS. The murine myeloid leukemia line 32Dp210, which has been derived by transfecting myeloid progenitor cell line 32Dcl3 with BCR/ABL oncogene was obtained from Dr Fowler of the National Cancer Institute, Bethesda, MD, USA. 32Dp210 leukemia cells were also maintained in RPMI-1640 tissue culture medium. All cell lines were passaged at 4 day intervals by seeding 1 × 10 6 cells in 10 ml of culture medium.
Hematopoietic progenitor cells
Normal mouse bone marrow cells were used as a source of hematopoietic progenitor cells in these experiments. Tibial and femoral bones of normal mice were removed under aseptic conditions and flushed with cold phosphate-buffered saline (PBS). Cells were washed two times in PBS and resuspended in 5 ml of Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal bovine serum, 30% culture medium conditioned by WEHI-3B cells and recombinant mouse stem cell factor (rmSCF) (R & D Systems, Minneapolis, MN, USA). Cells were used in experiments without pre-incubation to remove adherent stromal cells.
Clonal growth assay
Leukemias: The effect of resveratrol on cell proliferation was measured in clonogenic assays. For clonal expansion of leukemia cells, 2 × 10 3 leukemia cells were resuspended in 1 ml of complete RPMI-1640 culture medium containing 0.3% agar. Cell suspensions with or without known concentrations of resveratrol, as indicated in individual experiments, were plated (1 ml each) in 35 mm plastic Petri dishes in duplicate. Petri dishes were incubated at 37°C in humidified and 5% CO 2 atmosphere for 7 days. Dishes were scored for colonies (Ͼ50 cells) formed using an inverted microscope.
Hematopoietic progenitor cells:
For clonal expansion of hematopoietic cells, 1 × 10 4 bone marrow cells in 1 ml of MethoCult 3534 (Stem Cell Technologies) were placed in 35 mm plastic Petri dishes in duplicate with or without resveratrol. The MethoCult 3534 tissue culture medium consists of 1.1% methylcellulose in IMDM supplemented with rm IL3 (10 ng/ml), rh IL6 (10 ng/ml) and rm SCF (50 ng/ml).This medium supports the growth of CFU-GM, CFU-M and CFU-G colonies. Dishes were incubated at 37°C for 7 days and all colonies developed (CFU-total), including CFU-GM (ෂ60%), CFU-M (15-20%), CFU-G (Ͻ15%) and some pre-B cell colonies (Ͻ5%) were scored.
DNA fragmentation
To determine whether resveratrol induces apoptosis, 6 × 10 6 leukemia cells were treated with resveratrol (40 m) for 6 h or the same number of BM cells was treated at 80 m for 20 h. Cells were washed with PBS and then lysed in cold lysis solution (5 mm of Tris, pH 7.4, 20 mm of EDTA, 0.5% Triton X-100) for 20 min. Cell lysates were centrifuged at 27 000 g for 15 min, and DNA was extracted from the aqueous phase with phenol:chloroform:isoamyl alcohol (25:24:1, by vol) containing 0.1% hydroxyquinoline. DNA was precipitated with 0.3 m of sodium acetate and 2 vol of cold 100% ethanol. DNA specimens isolated from equal numbers of untreated and treated cells were fractionated on 1.2% agarose gel in Tris-acetate (0.04 m Tris-acetate, 0.001 m EDTA) electrophoresis buffer. Following fractionation of DNA, gels were treated with RNase (20 g/ml) for 3 h and stained with ethidium bromide.
BM transplantation
For transplantation of BM cells mice were given 10 Gy of radiation (Cs-137 Source) at a rate of 1.47 Gy/min in two equal doses of 5 Gy 8 h apart. Mice were either left without injection of normal bone marrow cells or were injected i.v. with 2 × 10 6 BM cells that were untreated or treated with resveratrol (80 m) for 20 h. Mice were followed for survival and peripheral blood cell counts were periodically monitored for hematologic recovery.
Results
Antiproliferative effect of resveratrol
Whether resveratrol inhibits the proliferation of leukemic and normal hematopoietic progenitor cells was examined by measuring the effect of different concentrations of resveratrol (eg 10-80 m) on clonal expansion of these cells in vitro. The desired concentration of resveratrol was incorporated in culture medium, 0.3% agar in the case of leukemias, and 1.1% methylcellulose (MethoCult GF 3534 medium) for BM progenitor cells, and was constantly present during the entire period of incubation of cultures. Figure 1 shows the dose-response effect of resveratrol on leukemias ( Figure 1a ) and BM progenitors ( Figure 1b) . Resveratrol inhibited the proliferation of all four leukemic cell lines tested (32Dp210, HL-60, U937 and L1210) in a dose-related manner. The maximum suppression (Ͼ98%) was seen at 80 m resveratrol. There was roughly 70-80% suppression of colony development by leukemic cell lines at 40 m resveratrol. Lower concentrations of resveratrol were not as inhibitory. The IC 50 of resveratrol for 32Dp210, HL-60, U937 and L1210 cells was found to be 18, 20, 26 and 34 m, respectively. Although resveratrol also reduced the clonal expansion of normal hematopoietic progenitor cells (55-60%), progenitor cells were less sensitive to the inhibitory effect of resveratrol than leukemia cells. At the highest concentration (80 m), resveratrol inhibited the clonal growth of leukemia cells by more than 98%, the inhibition of normal progenitor cell growth was 55-60%. The IC 50 of resveratrol for normal BM progenitor cells was substantially higher (59 m) than that for leukemia cell lines.
The inhibitory effect of resveratrol on leukemias or BM progenitor cells was not due to DMSO used for dissolving resveratrol, since equivalent concentrations of DMSO alone had no effect on the clonal expansion of these cells (data not shown). Overall, leukemia cells exhibited greater sensitivity to resveratrol compared to BM progenitors. 
Reversibility of resveratrol effect
In order to determine whether the anti-proliferative effect of resveratrol on leukemia cells and BM progenitors is irreversible or reversible, cells were pre-treated with 80 m resveratrol for 20 h. Cells were washed three times and then clonal cultures were initiated as described. Figure 2a shows complete suppression of colony development by leukemia cells if resveratrol is continuously present in the cultures. There was slight reversal (5-15%) of suppression of leukemic cell growth if resveratrol is removed after 20 h. In contrast, the reversal of the suppressive effect on BM progenitor cells was substantially higher (60-65%) (Figure 2b ). The reversal of the inhibitory effect of resveratrol on BM progenitors was consistently seen in all experiments (n = 4). In 32Dp210 clonal growth assay, both when 
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resveratrol was continuously present in cultures or was removed after treating cells for 20 h, the leukemic colonies that developed were smaller in size and reduced in cellularity (Figure 3b and c vs a) .
Resveratrol induces DNA fragmentation in leukemia cells
In an attempt to determine the mechanism by which resveratrol inhibits clonal growth of malignant and normal hematopoietic progenitor cells, we examined if resveratrol induces programmed cell death. 32Dp210, L1210 or HL-60 leukemia cells were treated with 40 m resveratrol for 6 h and assessed for DNA fragmentation by agarose gel electrophoresis. Results shown in Figure 4a demonstrate lack of apoptosis in untreated leukemia cells (lanes 2, 4
Bone Marrow Transplantation Taken together, these data demonstrate that resveratrol induces apoptosis in leukemia cells whereas normal bone marrow cells spontaneously undergo apoptosis after their removal from the animal, which is not affected by resveratrol.
Engraftment of resveratrol-treated BM cells
The results of in vitro experiments described above suggested that normal hematopoietic progenitor cells are less sensitive to the growth inhibitory activity of resveratrol compared to leukemia cells. To determine whether resveratrol-treated hematopoietic progenitor cells maintain their ability to engraft, we compared the engraftment of untreated and resveratrol-treated normal bone marrow cells in lethally irradiated mice. For this purpose, irradiated mice (10 Gy) were injected i.v. with 2 × 10 6 untreated BM cells or cells that were treated with 80 m resveratrol for 20 h and then washed free of the drug before injection. Mice were observed for survival, and for hematological recovery by taking blood cell counts and assessing colony-forming units in the marrow on day 30 after transplantation. As shown in Figure 5 , all lethally irradiated mice not injected with bone marrow cells (n = 11) died with an average survival time of 13.3 ± 2.1 s.d. days. All mice injected with untreated BM cells (n = 10) were alive on day 30. Two of the 12 mice that received resveratrol-treated bone marrow cells died on days 3 and 5, respectively; all remaining mice were alive on day 30. Although the cause of death of two mice that were injected with resveratrol-treated bone marrow cells could not be determined, it appears to be unrelated to the failure of engraftment of BM transplant, since mice that received no bone marrow support did not start dying before day 12.
Data in Table 1 show total WBC, RBC and platelets in mice injected with untreated or resveratrol-treated BM cells. Except for slow hematologic recovery in mice given treated NBM in the early periods following transplant, blood cell counts (RBC, WBC and platelets) were comparable in both groups 30 days after transplantation.
We also compared the level of hematopoietic progenitors in the marrow (tibia and femur) of mice that received untreated and resveratrol-treated BM cells on day 30 post transplantation. Even though the number of progenitors in the marrow of mice transplanted with untreated BM cells or resveratrol-treated BM cells was 30-40% less compared to normal control mice, there was no difference in the number of colony-forming units-total (CFU-total) (CFU-GM, CFU-M, CFU-G) in marrow cells obtained from mice injected with untreated or treated BM cells ( Figure 6 ). Taken together, these results indicate that treatment of bone marrow cells with resveratrol does not impede the engraftment of bone marrow.
Discussion
By using different human and mouse leukemia cell lines, our studies demonstrate that resveratrol inhibits the proliferation of leukemia cells in a dose-related manner. The growth inhibitory activity of resveratrol for both human and mouse leukemia cells ranged between IC 50 of 18 and 34. The long-term exposure to resveratrol also inhibited the clonal expansion of normal hematopoietic progenitor cells but at an IC 50 that was higher (IC 50 = 59) compared to leukemia cell lines. The difference between the sensitivity of leukemia cell lines and normal hematopoietic progenitors was also evident in experiments in which the recovery from growth suppression following the removal of resveratrol 4 cell/ml. One ml of cell suspension was added to each 35 mm Petri dish in duplicate. Total number of colonies (CFU-total) formed was scored 7 days after incubation at 37°C. Data presented are a mean CFU-total ± s.d.
from cultures was measured. There was only a slight recovery (5-15%) in the colony-forming capacity of leukemia cells following the removal of resveratrol after treating cells for 20 h at 80 m. In contrast, the recovery from growth suppression of hematopoietic progenitor cells following the removal of resveratrol after similar periods of treatment at 80 m was superior compared to that of leukemia cells (60-65%). These results suggest that although resveratrol inhibits the growth of both leukemic and normal hematopoietic progenitors, the anti-leukemic effect is for the most part irreversible, whereas normal progenitor cells significantly recover from the inhibitory effect of resveratrol. Resveratrol also induced nucleosomal DNA fragmentation in leukemia cells, suggesting that the inhibitory effect of resveratrol on these cells is, at least partially, mediated by the induction of apoptosis. On the other hand, normal hematopoietic progenitor cells were found to undergo apoptosis spontaneously, and this was not affected by treating cells with resveratrol. These data suggest that unlike leukemia cells the inhibition of normal progenitor cells by resveratrol is mediated by a mechanism other than apoptosis. The reversal of the inhibitory effect of resveratrol on normal hematopoietic cells, as seen in the recovery experiments, would also suggest that induction of apoptosis is not the part of the mechanism by which resveratrol inhibits the growth of normal progenitor cells. In the case of leukemia cells, it remains unclear whether there is any relationship between the inhibitory effect of resveratrol on arachidonate and lipid metabolism 16, 18 protein-tyrosine kinase 22 or topoisomerase 11 23 and the induction of apoptosis and growth inhibition. Recently, resveratrol was shown to induce apoptosis in HL-60 cells by capsase activation via the CD95 signaling pathway. 24 Whether apoptotic death in other leukemic cells by resveratrol is also mediated through CD95 and capsase activation remains to be determined.
In a recent report, resveratrol was shown to inhibit all three major stages of carcinogenesis, ie tumor initiation, promotion and progression. 20 The chemopreventive activity of resveratrol against chemical carcinogenesis is believed to be attributable to its ability to inhibit cyclo-oxygenase (COX-1) activity, free radical formation or induction of quinone reductase activity capable of detoxifying carcinogens. 20 The inhibition of proliferation of HL-60 cells by resveratrol was shown to be associated with terminal differentiation to non-proliferative granulocyte and monocyte/ macrophage phenotypes. 20 Whether the inhibition of the proliferation of leukemic cell lines by resveratrol in the present study also involves terminal differentiation in addition to apoptosis is not known. Together, the results of the published reports and those of the present study suggest that multiple mechanisms are involved in resveratrol mediated cell death in leukemia cells.
The reversibility of growth inhibitory effect of resveratrol on hematopoietic progenitors prompted us to examine the engraftment of bone marrow cells treated with resveratrol. Our data demonstrate excellent hematopoietic recovery of lethally irradiated mice injected with resveratrol-treated bone marrow graft. With the exception of two mice that died during the first few days of injection of resveratroltreated bone marrow cells, all other mice fully reconstituted hematologically within 30 days of transplantation. The number of hematopoietic progenitor cells in the marrow of mice injected with untreated or treated bone marrow cells was also comparable. The reason why the two mice which received resveratrol-treated marrow died is not known, but since they died within 5 days of cell injection these deaths appear to be unrelated to the failure of resveratrol-treated bone marrow cells to engraft. At this point, we do not know if there are differences in the sensitivity of primitive hematopoietic stem cells and more differentiated progenitor cells to resveratrol. Since roughly 30% of normal bone marrow cells failed to recover from the suppressive effect of resveratrol after its removal from cultures, some of the colonyforming units may also be irreversibly affected by resveratrol. On the other hand, since the recipients of treated bone cells fully engrafted suggests that enough hematopoietic progenitor cells are spared to allow complete hematopoietic reconstitution. In addition, the oligonucleosomal length DNA fragmentation that occurs spontaneously in progenitor cells also appears not to severely hamper their engraftment. To the best of our knowledge, this is the first report that describes the differential effect of resveratrol on leukemic and non-leukemic normal hematopoietic progenitor cells.
